关于金陵药业股份有限公司 非经营性资金占用及其他关联资金往来情况的 专项报告 信会师报字[2025]第 ZH10013 号 您可使用手机"扫一扫"或进入"注册会计师行业统一监管平台（bttp://ac.cnof.ess.co）"进行室 "疫可使用手机"扫一扫"或进入"注册会计师行业统一监管平台（bttp://ac.nof.eov.co）"进行室 。" 立信会计师事务所(特殊普通合伙) O CHINA SHU LUN PAN CERTIFIED PUBLIC ACCOUNTANTS LL 关于金陵药业股份有限公司 非经营性资金占用及其他关联资金往来情况 的专项报告 信会师报字[2025]第 ZH10013 号 金陵药业股份有限公司全体股东: 我们审计了金陵药业股份有限公司(以下简称"金陵药业")2024 年度的财务报表,包括 2024年 12月 31 日的合并及母公司资产负债 表、2024 年度合并及母公司利润表、合并及母公司现金流量表、合 并及母公司所有者权益变动表和相关财务报表附注,并于 2025年 3 月 27 日出具了报告号为信会师报字[2025]第 ZH10009 号的无保留意 见审计报告。 金陵药业 ...

您可使用手机"扫一扫"或进入"注册会计师行业统一监管平台（http://acc.mof.gov.cn/ 您可使用手机"扫一扫"或进入"注册会计师行业统一监管平台（http://acc.mof.gov.cn) "进行查 c.mor.gov.cn25X3B0 立信会计师事务所(特殊普通合伙) CHINA SHU LUN PAN CERTIFIED PUBLIC ACCOUNTANTS LL 关于金陵药业股份有限公司 2024年度募集资金存放与使用情况 专项报告的鉴证报告 信会师报字[2025]第ZH10012号 会陵药业股份有限公司全体股东: 我们接受委托,对后附的金陵药业股份有限公司(以下简称"金 陵药业")2024年度募集资金存放与使用情况专项报告(以下简称"募 集资金专项报告")执行了合理保证的鉴证业务。 关于金陵药业股份有限公司 2024 年度募集资金存放与使用情况 专项报告的鉴证报告 信会师报字[2025]第 ZH10012 号 一、董事会的责任 金陵药业董事会的责任是按照中国证券监督管理委员会《上市公 司监管指引第2号 -- 上市公司募集资金管理和使用的监管要求 (2022年修订)》(证监会公告〔20 ...

金陵药业股份有限公司 独立董事2024年度述职报告 各位股东及代表： 2023 年 6 月 28 日，金陵药业股份有限公司（以下简称"公司"） 2023 年第二次临时股东大会选举本人沈永建担任第九届董事会独立 董事。同日召开的公司第九届董事会第一次会议选举本人担任董事会 审计委员会的召集人，以及董事会提名委员和薪酬与考核委员会委员。 2024 年度，本人作为公司的独立董事按照《公司法》《上市公司 治理准则》和《上市公司独立董事管理办法》等法律法规以及《公司 章程》的规定，本着客观、公正、独立的原则，及时了解公司各方面 的经营状况；按时出席公司股东大会和董事会，认真审议董事会各项 议案，对公司相关事项发表独立意见，并对各项议案进行表决，积极 发挥独立董事作用，维护公司整体利益和全体股东尤其是中小股东的 合法权益。 一、独立董事的基本情况 （一）个人简介 本人沈永建，男，1978 年出生，博士、博士后、教授，博士研究 生导师。现任南京财经大学会计学院教授。 报告期内，本人未在公司担任除独立董事以外的任何职务，也未 在公司主要股东公司担任任何职务，与公司以及主要股东之间不存在 利害关系或其他可能妨碍其进行独立客观判 ...

金陵药业股份有限公司 独立董事2024年度述职报告 各位股东及代表： 2024年度，本人作为公司的独立董事按照《公司法》《上市公司 治理准则》和《上市公司独立董事管理办法》等法律法规以及《公司 章程》的规定，本着客观、公正、独立的原则，及时了解公司各方面 的经营状况；按时出席公司股东大会和董事会，认真审议董事会各项 议案，对公司相关事项发表独立意见，并对各项议案进行表决，积极 发挥独立董事作用，维护公司整体利益和全体股东尤其是中小股东的 合法权益。 一、独立董事的基本情况 本人寇俊萍，女，1972 年出生，博士，教授，博士生导师。现 任中国药科大学中药学院教授。 现将 2024 年度的任职情况向股东大会汇报如下： 二、独立董事 2024 年度履职概况 （二）独立性的情况说明 2023 年 6 月 28 日，金陵药业股份有限公司（以下简称"公司"） 2023 年第二次临时股东大会选举本人寇俊萍担任第九届董事会独立 董事。同日召开的公司第九届董事会第一次会议选举本人担任董事会 提名委员会的召集人，以及董事会战略委员会委员、薪酬与考核委员 和审计委员会委员。 （一）个人简介 报告期内，本人未在公司担任除独立董事以外 ...

金陵药业股份有限公司 独立董事2024年度述职报告 各位股东及代表： 2023 年 6 月 28 日，金陵药业股份有限公司（以下简称"公司"） 2023 年第二次临时股东大会选举本人高燕萍担任第九届董事会独立 董事。同日召开的公司第九届董事会第一次会议选举本人担任董事会 薪酬与考核委员会的召集人，以及董事会战略委员会委员、提名委员 和审计委员会委员。 2024 年度，本人作为公司的独立董事按照《公司法》《上市公司 治理准则》和《上市公司独立董事管理办法》等法律法规以及《公司 章程》的规定，本着客观、公正、独立的原则，及时了解公司各方面 的经营状况；按时出席公司股东大会和董事会，认真审议董事会各项 议案，对公司相关事项发表独立意见，并对各项议案进行表决，积极 发挥独立董事作用，维护公司整体利益和全体股东尤其是中小股东的 合法权益。 一、独立董事的基本情况 （一）个人简介 本人高燕萍，女，1963 年出生，博士。历任上海复旦医院管理 有限公司副总经理、上海美华医疗集团副总裁、担任瑞典医疗健康发 展集团副总裁、中国上海办事处首席代表、上海歆柏医院管理有限公 司总经理，现任上海康程医院管理咨询有限公司总裁、副董事长、 ...

Financial Performance - The basic earnings per share decreased by 67.63% to 0.0682 yuan in 2024 from 0.2107 yuan in 2023 [1] - Net profit fell by 62.26% to 0.4 billion yuan in 2024 compared to 1.06 billion yuan in 2023 [1] - Operating revenue increased by 2.72% to 32.81 billion yuan in 2024 from 31.94 billion yuan in 2023 [1] - The return on equity dropped by 66.97% to 1.09% in 2024 from 3.30% in 2023 [1] Shareholder Structure - The top ten unrestricted shareholders hold a total of 29,652.44 million shares, accounting for 50.22% of the circulating shares, with a change of 4.19 million shares from the previous period [1] - Nanjing New Industry Investment Group Co., Ltd. remains the largest shareholder with 22,794.38 million shares, representing 38.61% of total share capital [2] - New entrants among the top shareholders include Liu Ping and Nanjing Xiechen Electronic Technology Co., Ltd. [2] Dividend Distribution - The company announced a dividend distribution plan of 1 yuan per share (including tax) [3]

Financial Performance - The company's operating revenue for 2024 reached ¥3,281,450,555, representing a 2.74% increase compared to ¥3,193,999,850 in 2023[21]. - The net profit attributable to shareholders decreased by 61.95% to ¥40,409,795.7 from ¥106,193,864 in the previous year[21]. - The net cash flow from operating activities was ¥154,190,609, down 27.28% from ¥212,024,737 in 2023[21]. - Basic earnings per share fell by 67.63% to ¥0.0682 from ¥0.2107 in 2023[21]. - Total assets increased by 10.86% to ¥6,088,855,020 compared to ¥5,492,591,080 in 2023[22]. - The net assets attributable to shareholders rose by 17.22% to ¥3,791,090,830 from ¥3,234,294,840 in the previous year[22]. - The company achieved total operating revenue of 328,145.06 million yuan and a net profit attributable to the parent company of 4,040.98 million yuan during the reporting period[49]. - The total revenue for the reporting period was ¥3,281,450,554.7, representing a year-on-year increase of 2.74% from ¥3,193,999,854.5[61]. - Revenue from pharmaceutical production and sales decreased by 3.93% to ¥1,493,178,383.1, while medical services revenue increased by 10.83% to ¥1,740,050,342.0[61]. Dividend Distribution - The company plans to distribute a cash dividend of 1 RMB per 10 shares to all shareholders, based on a total of 623,708,628 shares[3]. - The company reported a cash dividend of 1.00 yuan per 10 shares, totaling 62,370,862.80 yuan for the reporting period[162]. - The cash dividend distribution accounted for 100% of the total profit distribution amount[162]. - The total distributable profit available for shareholders at the end of 2024 is 889,118,106.16 yuan, after accounting for the net profit and dividends paid[164]. - The company’s profit distribution policy was executed in accordance with its articles of association, ensuring the protection of minority shareholders' rights[162]. Business Operations and Changes - The company has undergone business changes, expanding from pharmaceutical manufacturing to include medical services and health care services since 2003[19]. - The company operates in the pharmaceutical and medical device manufacturing sectors, focusing on traditional Chinese medicine and chemical drugs, with key products including "Mailuo Ning Injection" and "Ferrous Succinate Tablets"[43]. - The company has maintained a stable revenue stream, with a low debt ratio and financial leverage, indicating strong financial health[48]. - The company has implemented a management model that integrates investment management and operational oversight across its subsidiaries, ensuring strategic alignment and resource optimization[44]. - The company is actively expanding its healthcare services, including integrated medical and elderly care services, to meet the growing demand in the market[45]. Market Trends and Industry Insights - The pharmaceutical manufacturing industry in China achieved a revenue of ¥3.5 trillion in 2024, growing by 8.5% year-on-year[31]. - The overall medical service market size in 2024 is estimated at 4.8 trillion yuan, reflecting a 9% year-on-year increase[33]. - The elderly medical consumption market size is projected to reach 2.2 trillion yuan in 2024, with a year-on-year growth of 10%[35]. - The number of remote medical service institutions is anticipated to grow by 20% in 2024, reaching 150,000[34]. - Online consultation volume is expected to increase by 30% in 2024, reaching 1 billion consultations[34]. Research and Development - Investment in innovative drug research and development increased to 15% of total revenue, up 2 percentage points from the previous year[31]. - The company invested ¥110,692,200 in research and development during the reporting period, maintaining growth in R&D expenditure[57]. - The company reported a total R&D expenditure of ¥110,692,239.54, an increase of 39.86% compared to ¥79,143,338.26 in the previous year, representing 3.37% of total revenue[75]. - The number of R&D personnel increased by 16.79% to 153, with a notable rise in the number of master's and doctoral degree holders[74]. - The company has a robust drug pipeline, with multiple projects in various stages of development, including drugs for chronic heart failure and advanced breast cancer[58][59]. Acquisitions and Investments - The acquisition of a 51% stake in Nanjing Meishan Hospital was completed, enhancing the company's medical service sector and resolving competition issues with the controlling shareholder[53]. - The company completed a stock issuance to specific investors, with funds received on March 25, 2024, to support key projects[52]. - The company is actively pursuing partnerships and collaborations to enhance its research capabilities and product offerings[56]. - The company is exploring potential acquisitions to enhance its product portfolio, targeting companies with annual revenues of $50 million to $200 million[135]. Governance and Compliance - The company has implemented a governance structure that complies with relevant laws and regulations, enhancing its governance level[114]. - The board of directors operates independently, with independent directors having sufficient access to information to fulfill their duties[115]. - The company has established an independent financial department with a standardized accounting system and separate bank accounts, ensuring independent tax compliance[118]. - The company has disclosed its "Quality and Return Dual Improvement" action plan, indicating a commitment to enhancing quality and returns[112]. - The company has maintained effective internal controls in all significant aspects of financial reporting[174]. Environmental Responsibility - The company has implemented a VOCs "one enterprise, one policy" governance plan since 2021 to improve air quality[191]. - The company has actively participated in the "waste-free factory" initiative and received certification as a "waste-free factory" in Nanjing[190]. - The company paid 11,729.83 yuan in environmental protection tax for the year 2024[190]. - The company has implemented "rainwater and sewage diversion" systems at its facilities to enhance wastewater treatment efficiency[186]. - Jinling Pharmaceutical Factory's average COD discharge concentration in 2024 was 78.3 mg/L, significantly below the limit of 500 mg/L[186]. Employee Management and Training - The total number of employees at the end of the reporting period was 5,789, with 882 in the parent company and 4,907 in major subsidiaries[156]. - The company conducted 1,273 training sessions in 2024, with a total training investment exceeding 5 million yuan, achieving a 100% training coverage rate[159]. - The company has a performance-oriented compensation policy, linking employee salaries to individual, departmental, and overall company performance[158]. - The average training hours per employee were approximately 2 hours, reflecting the company's commitment to talent development[159]. - The company has a diverse management team with various roles, including a total of 8 assistant presidents[140][141].

关于公司董事会审计委员会对会计师事务所 2024 年度履行 监督职责情况的报告 根据《中华人民共和国公司法》《中华人民共和国证券法》《独 立董事管理办法》《深圳证券交易所上市公司自律监管指引第 1 号 ——主板上市公司规范运作》《国有企业、上市公司选聘会计师事务 所管理办法》和《公司章程》等规定和要求，金陵药业股份有限公司 （以下简称"本公司"）董事会审计委员会本着勤勉尽责的原则，恪 尽职守，认真履职。现将董事会审计委员会对会计师事务所 2024 年 度履行监督职责的情况汇报如下： 一、2024年度会计师事务所基本情况 (一)会计师事务所基本情况 1、会计事务所名称：立信会计师事务所（特殊普通合伙） 2、成立时间：2011年1月24日 3、组织形式：特殊普通合伙 4、注册地址：上海市黄浦区南京东路 61 号四楼 5、经营范围：审查企业会计报表，出具审计报告；验证企业资 本，出具验资报告；办理企业合并、分立、清算事宜中的审计业务， 出具有关报告；基本建设年度财务决算审计；代理记账；会计咨询、 税务咨询、管理咨询、会计培训；信息系统领域内的技术服务；法律、 法规规定的其他业务。（依法须经审批的项目，经相关部门批准 ...